Skip to content

BCBS Rhode Island

Does BCBS Rhode Island cover Wegovy?

Yes. BCBS Rhode Island covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 30 kg/m2

Adult overweight with comorbidity

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m2

Plus any one of:

  • Hypertension
  • T2DM
  • dyslipidemia
  • OSA
  • CVD
  • MASH

Pediatric obesity (age 12+)

All of:

  • Age ≥ 12 years
  • BMI at or above 95th percentile for age and sex

Asian adult overweight/obesity

All of:

  • BMI ≥ 23 kg/m2 (South Asian, Southeast Asian, or East Asian adults)

Documentation to bring

  • Baseline BMI documentation
  • Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
  • Age documentation (≥ 12 years for pediatric; ≥ 18 years for adult)

Approval and renewal

  • Renewal: Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose.
  • Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: Document covers both Wegovy injection and Wegovy tablet formulations. Wegovy HD (high-dose semaglutide) is also listed as a separate formulation for weight loss in adults. Efficacy should be assessed after 12 weeks at therapeutic dose; continuation only if ≥ 5% weight loss achieved and therapy tolerated. Pediatric patients aged 12+ with obesity (BMI ≥ 95th percentile) are included per FDA labeling.

Policy effective May 4, 2026 · verified June 2, 2026 · source: Ri Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CVD and overweight/obesity without diabetes

All of:

  • Age ≥ 45 years
  • BMI ≥ 27 kg/m2
  • Established cardiovascular disease
  • Without diabetes (SELECT trial enrolled patients without diabetes)

Documentation to bring

  • Documentation of established cardiovascular disease
  • Baseline BMI ≥ 27 kg/m2
  • Confirmation that patient does not have diabetes (SELECT trial basis)

Not covered when

  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended
  • SELECT trial excluded patients with diabetes; document notes CV indication is independent of diabetes status per FDA label but trial population was without diabetes

Policy note: The SELECT trial (NCT03574597) enrolled adults ≥ 45 years with BMI ≥ 27 kg/m2, established CVD, and without diabetes. The document references this trial as supporting CV risk reduction. The FDA indication covers adults with established CV disease and either obesity or overweight. The clinical rationale notes the CV benefit is 'independent of diabetes status' but the trial itself excluded patients with diabetes, hence excludes diabetes set to true based on trial population.

Policy effective May 4, 2026 · verified June 2, 2026 · source: Ri Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with moderate-to-advanced fibrosis

All of:

  • Adult patient (age ≥ 18)
  • Noncirrhotic MASH diagnosis
  • Fibrosis stage F2 to F3 confirmed by appropriate diagnostic method

Plus any one of:

  • Liver biopsy confirming MASH with F2-F3 fibrosis
  • FIB-4 elevated (> 1.30 low-risk threshold) with confirmatory ELF and/or elastography (VCTE or MRE) consistent with F2-F3
  • ELF score ≥ 9.8 (intermediate risk) or ≥ 11.3 (high risk) with corroborating fibrosis staging
  • VCTE ≥ 8 kPa (intermediate) or ≥ 12 kPa (high risk/advanced fibrosis)

Documentation to bring

  • Diagnosis of noncirrhotic MASH
  • Evidence of fibrosis stage F2 or F3 via liver biopsy, FIB-4 with confirmatory elastography (VCTE/MRE), or ELF test
  • FIB-4 result (primary risk stratification): low-risk < 1.30, indeterminate 1.30–2.67, high-risk > 2.67 (for age > 65, high-risk threshold > 2.0)
  • If FIB-4 indeterminate or elevated: confirmatory ELF and/or elastography results
  • Confirmation patient does not have cirrhosis

Not covered when

  • Cirrhotic MASH excluded (noncirrhotic only per FDA labeling)
  • Fibrosis stage F4 (cirrhosis) excluded
  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: FDA indication is for noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). The document outlines a stepwise diagnostic approach: Step 1 FIB-4 (primary risk stratification with cutoffs < 1.30 low, 1.30-2.67 indeterminate, > 2.67 high; age > 65 high threshold > 2.0), Step 2 ELF and/or elastography (VCTE/MRE) for confirmatory testing. ELF cutpoints: < 9.8 low risk, 9.8-11.3 intermediate, ≥ 11.3 high risk. VCTE cutpoints: < 8 kPa low, 8-12 kPa intermediate, ≥ 12 kPa high risk/advanced fibrosis. MRE may be used when uncertainty persists. Biopsy reserved for indeterminate/discordant NITs or suspected alternate etiologies. The NASH trial (NCT04822181) enrolled biopsy-confirmed MASH with F2-F3 and NAS ≥ 4. Imaging lookback set to 6 months for elastography; lab lookback set to 6 months for serum biomarkers (FIB-4, ELF) based on clinical guidance context, though specific lookback periods not explicitly stated in available document text.

Policy effective May 4, 2026 · verified June 2, 2026 · source: Ri Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Rhode Island cover Wegovy?
Yes. BCBS Rhode Island covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
What does BCBS Rhode Island require to renew Wegovy?
Weight Loss — Applies to Employer and ACA Marketplace plans. Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose. At least 12 weeks on therapy before the first renewal.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Rhode Island: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Rhode Island's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.